5 Biotechs Investors Should Keep on Their Radar in Q1
This year is starting off with a bang for several biotechs. There's a lot going on, from important clinical updates to regulatory decisions. Here's why Amgen, Jazz Pharmaceuticals, Lexicon Pharmaceuticals, Regeneron Pharmaceuticals and Synergy Pharmaceuticals are five biotech stocks you'll definitely want to watch in the first quarter.
Amgen: Two big events
Amgen failed to win approval from the U.S. Food and Drug Administration on its first try with experimental secondary hyperparathyroidism (sHPT) drug Parsabiv. The big biotech thinks it resolved the issues identified by the FDA and resubmitted for approval. A decision is expected by Feb. 9.
Amgen: Two big events
Amgen failed to win approval from the U.S. Food and Drug Administration on its first try with experimental secondary hyperparathyroidism (sHPT) drug Parsabiv. The big biotech thinks it resolved the issues identified by the FDA and resubmitted for approval. A decision is expected by Feb. 9.